Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
Gerald HJ Mickisch1, Björn Schwander2, Bernard Escudier3, Joaquim Bellmunt4, José P Maroto5, Camillo Porta6, Stefan Walzer7, Uwe Siebert8,91Department of Urology, Center of Operative Urology Bremen, Bremen, Germany; 2Department of Outcomes Research, AiM GmbH Assessment-in-Medicin...
Saved in:
Main Authors: | Gerald HJ Mickisch (Author), Björn Schwander (Author), Bernard Escudier (Author), et al (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2011-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024) -
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
by: Jianling Bi, et al.
Published: (2021) -
Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
by: Wu J, et al.
Published: (2020) -
ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro
by: Skoglund K, et al.
Published: (2013) -
Tyrosine kinases in rheumatoid arthritis
by: Kobayashi Akiko, et al.
Published: (2011)